Ginkgo Bioworks Holdings, Inc.

Equities

DNA

US37611X1000

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 19:21:10 16/07/2024 BST			5-day change	1st Jan Change
0.354 ^USD	+22.03%		+14.16%	-79.15%

02:27pm	Ginkgo Bioworks Partners With Syngenta Crop Protection for new Biologicals	MT
07-09	Goldman Sachs Adjusts Price Target on Ginkgo Bioworks to $0.30 From $0.80, Maintains Sell Rating	MT

Ginkgo Bioworks Holdings, Inc. Appoints Behzad Mahdavi, Senior Vice President of Biopharma Manufacturing & Life Science Tools

January 06, 2023 at 12:00 pm

Ginkgo Bioworks Holdings, Inc. has also added expertise across its biopharma team, including the appointment of Dr. Behzad Mahdavi, senior vice president of biopharma manufacturing & life science tools.

Latest news about Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Partners With Syngenta Crop Protection for new Biologicals	01:27pm	MT
Goldman Sachs Adjusts Price Target on Ginkgo Bioworks to $0.30 From $0.80, Maintains Sell Rating	07-09	MT
Microba Life Sciences Completes Screening for Autoimmune Disease Program; Shares Down 3%	06-28	MT
Transcript : Ginkgo Bioworks Holdings, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-30-2024 10:40 AM	05-30
Transcript : Ginkgo Bioworks Holdings, Inc. Presents at TD. Cowen Virtual Sustainability & Energy Transition Summit, May-22-2024 03:25 PM	05-22
Ginkgo Bioworks Holdings Insider Bought Shares Worth $514,750, According to a Recent SEC Filing	05-16	MT
BTIG Downgrades Ginkgo Bioworks Holdings to Sell From Neutral, Price Target is $0.50	05-15	MT
Morgan Stanley Trims Ginkgo Bioworks Price Target to $1 From $2, Maintains Equal Weight Rating	05-15	MT
Ginkgo Bioworks Holdings Insider Bought Shares Worth $271,815, According to a Recent SEC Filing	05-14	MT
Ginkgo Bioworks Holdings Insider Sold Shares Worth $1,606,162, According to a Recent SEC Filing	05-14	MT
Ginkgo Bioworks Gets NYSE Noncompliance Notice on Minimum Closing Price	05-13	MT
William Blair Downgrades Ginkgo Bioworks Holdings to Underperform From Market Perform	05-10	MT
Ginkgo Bioworks Holdings Q1 Loss Narrows, Revenue Drops; 2024 Revenue Outlook Slashed; Cost Cuts Planned	05-09	MT
Ginkgo Bioworks Holdings, Inc. Updates Revenue Guidance for the Full Year 2024	05-09	CI
Transcript : Ginkgo Bioworks Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Earnings Flash (DNA) GINKGO BIOWORKS Posts Q1 Revenue $38M, vs. Street Est of $46M	05-09	MT
Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Ginkgo Bioworks, GreenLab Launch Partnership to Produce Sugar Substitute Brazzein	05-07	MT
GreenLab and Ginkgo Bioworks Announce New Partnership	05-07	CI
Il Granaio delle Idee and Ginkgo Bioworks Announces Strategic Collaboration to Optimize Sourdough Strains for Bakery Products	04-16	CI
Transcript : Ginkgo Bioworks Holdings, Inc. Presents at Ginkgo's Annual Ferment Conference 2024, Apr-11-2024	04-11
Ginkgo Bioworks Acquires AgBiome's Platform Assets	04-11	MT
Ginkgo Bioworks Expands Research Partnership With Novo Nordisk	04-10	MT
Ginkgo Bioworks Partners With IdeeLab Biotechnology in Brazil	04-08	MT
IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service	04-08	CI

Chart Ginkgo Bioworks Holdings, Inc.

Duration

Period

More charts

Company Profile

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ginkgo Bioworks Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.2901 USD

Average target price

1.3 USD

Spread / Average Target

+348.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GINKGO BIOWORKS HOLDINGS, INC.	-79.15%	646M
MODERNA, INC.	+25.39%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	-0.02%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.32%	32.4B
ICON PUBLIC LIMITED COMPANY	+20.78%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+48.46%	14.52B
MEDPACE HOLDINGS, INC.	+47.66%	13.74B
BIO-TECHNE CORPORATION	+3.46%	12.17B

Other Biotechnology & Medical Research